Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients
Olga Montvida, Kerenaftali Klein, Sudhesh Kumar, Kamlesh Khunti, Sanjoy K Paul
Diabetes Obesity and Metabolism | WILEY | Published : 2017
BACKGROUND: Real world outcomes of addition or switch to insulin therapy in type 2 diabetes (T2DM) patients on glucagon-like paptide-1 receptor agonist (GLP-1RA) with inadequately controlled hyperglycaemia, are not known. MATERIALS AND METHODS: Patients with T2DM (n = 66 583) with a minimum of 6 months of GLP-1RA treatment and without previous insulin treatment were selected. Those who added insulin (n = 39 599) or switched to insulin after GLP-1RA cessation (n = 4706) were identified. Adjusted changes in glycated haemoglobin (HbA1c), weight, systolic blood pressure (SBP), and LDL cholesterol were estimated over 24 months follow-up. RESULTS: Among those who continued with GLP-1RA treatment w..View full abstract
We gratefully acknowledge the support for the QIMR Berghofer Institute from the Australian Government Department of Education's National Collaborative Research Infrastructure Strategy (NCRIS) initiative through Therapeutic Innovation Australia. No separate funding was obtained for this study. O. M. acknowledges the support from her associate supervisors Prof. Ross Young and Prof. Louise Hafner. K. Klein acknowledges support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care - East Midlands (NIHR CLAHRC - EM), and the NIHR Leicester Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit.